title: Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
abstract: OBJECTIVE
  To compare and contrast the efficacy and safety of patiromer and sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalemia.
  
  
  METHODS
  A systematic review and meta-analysis of phase II and III clinical trial data was completed.
  
  
  METHODS
  Eight studies (two phase II and four phase III trials with two subgroup analyses) were included in the qualitative analysis, and six studies (two phase II and four phase III trials) were included in the meta-analysis.
  
  
  RESULTS
  Significant heterogeneity was found in the meta-analysis with an I2value ranging from 80.6-99.6%. A random-effects meta-analysis was applied for all end points. Each clinical trial stratified results by hyperkalemia severity and dosing; therefore, these were considered separate treatment groups in the meta-analysis. For patiromer, a significant -0.70 mEq/L (95% confidence interval [CI] -0.48 to -0.91 mEq/L) change was noted in potassium at 4 weeks. At day 3 of patiromer treatment, potassium change was -0.36 mEq/L (range of standard deviation 0.07-0.30). The primary end point for ZS-9-change in potassium at 48 hours-was -0.67 mEq/L (95% CI -0.45 to -0.89 mEq/L). By 1 hour after ZS-9 administration, change in potassium was -0.17 mEq/L (95% CI -0.05 to -0.30). Analysis of pooled adverse effects from these trials indicates that patiromer was associated with more gastrointestinal upset (7.6% constipation, 4.5% diarrhea) and electrolyte depletion (7.1% hypomagnesemia), whereas ZS-9 was associated with the adverse effects of urinary tract infections (1.1%) and edema (0.9%).
  
  
  CONCLUSIONS
  Patiromer and ZS-9 represent significant pharmacologic advancements in the treatment of hyperkalemia. Both agents exhibited statistically and clinically significant reductions in potassium for the primary end point of this meta-analysis. Given the adverse effect profile and the observed time-dependent effects, ZS-9 may play more of a role in treating acute hyperkalemia.
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
authors.forename: Calvin J
authors.initials: CJ
authors.lastname: Meaney
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
authors.forename: Mario V
authors.initials: MV
authors.lastname: Beccari
authors.affiliation: Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.
authors.forename: Jiwei
authors.initials: J
authors.lastname: Zhao
mesh_terms: D004305:Dose-Response Relationship, Drug; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy* / Q000503:physiopathology; D011108:Polymers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D012720:Severity of Illness Index; D017640:Silicates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D017640:Silicates; C568789:patiromer; C000597310:sodium zirconium cyclosilicate; D011188:Potassium
keywords: ZS-9; hyperkalemia; patiromer; sodium polystyrene sulfonate; sodium zirconium cyclosilicate